{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:59:47Z","timestamp":1769317187636,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000104","name":"National Aeronautics and Space Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jgar.2020.03.014","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T11:10:49Z","timestamp":1585739449000},"page":"283-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Effects of caspofungin, tolcapone and other FDA-approved medications on MRSA susceptibility to vancomycin"],"prefix":"10.1016","volume":"22","author":[{"given":"Jonah A.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Meakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikaela H.","family":"Earl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany M.","family":"Kummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy P.","family":"McAleer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.03.014_bib0005","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/cid\/cix640","article-title":"Staphylococcus aureusTrends in methicillin-resistant hospitalizations in the United States, 2010-2014","volume":"65","author":"Klein","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.03.014_bib0010","series-title":"Active bacterial core surveillance report, Emerging Infections Program Network, methicillin-resistant Staphylococcus aureus","author":"Centers for Disease Control and Prevention","year":"2015"},{"key":"10.1016\/j.jgar.2020.03.014_bib0015","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0025-7125(05)70294-7","article-title":"Antibiotic synergy and antagonism","volume":"84","author":"Acar","year":"2000","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jgar.2020.03.014_bib0020","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1128\/AAC.02463-14","article-title":"Antagonism between bacteriostatic and bactericidal antibiotics is prevalent","volume":"58","author":"Ocampo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.03.014_bib0025","series-title":"Methods for dilution antimicrobial tests for bacteria that grow aerobically.: approved standard","author":"M07-A10","year":"2015"},{"key":"10.1016\/j.jgar.2020.03.014_bib0030","article-title":"Synergy testing: broth microdilution checkerboard and broth macrodilution methods","volume":"vol 2","author":"Moody","year":"2010"},{"key":"10.1016\/j.jgar.2020.03.014_bib0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fmicb.2019.00801","article-title":"Optimisation of the protocol for the LIVE\/DEAD\u00ae BacLightTM bacterial viability kit for rapid determination of bacterial load","volume":"10","author":"Robertson","year":"2019","journal-title":"Front Microbiol"},{"issue":"12","key":"10.1016\/j.jgar.2020.03.014_bib0040","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jphp.12780","article-title":"Echinocandins in antifungal pharmacotherapy","volume":"69","author":"Patil","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.jgar.2020.03.014_bib0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CIA.S3787","article-title":"Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson\u2019s disease","volume":"4","author":"Truong","year":"2009","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jgar.2020.03.014_bib0050","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1086\/673157","article-title":"Staphylococcus aureusA systematic literature review and meta-analysis of factors associated with methicillin-resistant colonization at time of hospital or intensive care unit admission","volume":"34","author":"Mckinnell","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2020.03.014_bib0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fmicb.2015.00750","article-title":"Repurposing celecoxib as a topical antimicrobial agent","volume":"6","author":"Thangamani","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2020.03.014_bib0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0924-8579(03)00200-0","article-title":"Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro","volume":"22","author":"Kristiansen","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.03.014_bib0065","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2014.02.004","article-title":"Antibacterial properties of the CFTR potentiator ivacaftor","volume":"13","author":"Reznikov","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jgar.2020.03.014_bib0070","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1128\/AAC.44.5.1394-1396.2000","article-title":"Vancomycin and oxacillin synergy for methicillin-resistant staphylococci","volume":"44","author":"Domaracki","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.03.014_bib0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1128\/AAC.01888-13","article-title":"Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S. aureus isolates in vitro","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.03.014_bib0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jac\/35.1.53","article-title":"Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels","volume":"35","author":"Marchese","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.03.014_bib0085","doi-asserted-by":"crossref","first-page":"e00898","DOI":"10.1128\/AAC.00898-17","article-title":"Repurposing thiram and disulfiram as antibacterial agents for multidrug-resistant Staphylococcus aureus infections","volume":"61","author":"Long","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.03.014_bib0090","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0031-6997(24)01423-6","article-title":"Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors","volume":"51","author":"M\u00e4nnist\u00f6","year":"1999","journal-title":"Pharmacol Rev"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520300783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520300783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:42Z","timestamp":1761990822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520300783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":18,"alternative-id":["S2213716520300783"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.03.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of caspofungin, tolcapone and other FDA-approved medications on MRSA susceptibility to vancomycin","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}